Please login to the form below

LAMA

This page shows the latest LAMA news and features for those working in and with pharma, biotech and healthcare.

Looking back from the future, companies that marketed, say, insulin or LAMA/LABA drugs will seems like strange historical artefacts from another age.

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s
AZ prepares to file COPD triple, taking on rival GSK

The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –
AZ rival to GSK’s COPD drug Anoro fails head-to-head test

The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two
AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol,
EMA approves GSK’s triple COPD therapy

The same indication was approved by the FDA in September, and makes Trelegy the first drug on the market to combine an ICS, LABA and long-acting muscarinic receptor antagonist (LAMA)

More from news
Approximately 3 fully matching, plus 41 partially matching documents found.

Could formulary intelligence be your brand differentiator?

Spiolto – a LAMA/LABA combination for COPD and heir to Boehringer’s blockbuster Spiriva.
Medius Deal Watch table for February 2015

Collaboration - discover, develop, commercialise. 339. Theravance/ Mylan. TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD.
Pharma deals in February 2015

The co-development and marketing deal with Theravance involves TD-4208 a novel, phase 3 ready, once-daily, nebulised, long-acting muscarinic antagonist (LAMA) under development to treat COPD and other
Deal Watch table for June 2013

2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).
Pharma deals during June 2013

2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important new class of treatment.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Add my company

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....